Scholarlink

Introduction <p>The primary analysis of IMscin002 (NCT05171777) demonstrated that most patients preferred atezolizumab subcutaneous (SC) administration over intravenous (IV) administration; we report patient preference according to baseline characteristics, mean injection duration, and cumulative number of SC injections at each center from IMscin002.</p> Methods <p>In this phase&#xa0;2, randomized, open-label, crossover trial, patients aged ≥18&#xa0;years, with <i>EGFR</i>/<i>ALK</i> wild-type tumors and either PD-L1+ (≥ 1%) resected non-small cell lung cancer (NSCLC) (stage&#xa0;2, 3a, or selected 3b; AJCC 8th edition) with prior chemotherapy and no evidence of recurrence, or untreated PD-L1-high (≥ 50%) stage&#xa0;4 NSCLC were eligible. Patients, randomized 1:1, received atezolizumab IV or SC for three cycles before switching to the alternative formulation for another three cycles. Patients chose a formulation for the continuation period after cycle&#xa0;6. Primary endpoint: patient preference for atezolizumab SC/IV.</p> Results <p>Among 179 patients randomized, demographics and characteristics were generally balanced between arms. Overall, 87/123 patients (70.7%) preferred atezolizumab SC, of whom 86.2% had a very/fairly strong preference compared with 69.2% of patients who preferred IV (<i>n</i> = 26/123, 21.1%). Patient preference for atezolizumab SC was independent of baseline characteristics and mean injection duration. A higher proportion of preference was seen in patients aged &gt; 74&#xa0;years (87.5%). A trend for a greater number of patients preferring atezolizumab SC over IV was seen in patients at centers where a higher number of cumulative injections (&gt; 47 to ≤ 164) were administered before preference disclosure.</p> Conclusions <p>Most patients preferred atezolizumab SC regardless of baseline characteristics, mean injection duration, and cumulative number of SC injections. The trend for a stronger preference was higher among patients who preferred SC than those who preferred IV. Our findings suggest that the proportion of preference for atezolizumab SC over IV is highest in patients aged &gt; 74&#xa0;years, and that administrator’s experience could be an important factor influencing patient preference.</p> Clinical Trial Registration Number <p>NCT05171777.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Exploratory Analyses of Patient Preferences for Atezolizumab Subcutaneous Versus Intravenous from the IMscin002 Study in Patients with Non-Small Cell Lung Cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月26日

查看全文
  • Margarita Majem,
  • Busyamas Chewaskulyong,
  • Zanete Zvirbule,
  • Ki Hyeong Lee,
  • Ernesto Korbenfeld,
  • Jaroslaw Kolb-Sielecki,
  • Amparo Yovanna Castro Sanchez,
  • Alberto Bustillos,
  • Luis Herraez-Baranda,
  • Xiaoyan Liu,
  • Sang-We Kim,
  • Federico Cappuzzo

摘要

Introduction

The primary analysis of IMscin002 (NCT05171777) demonstrated that most patients preferred atezolizumab subcutaneous (SC) administration over intravenous (IV) administration; we report patient preference according to baseline characteristics, mean injection duration, and cumulative number of SC injections at each center from IMscin002.

Methods

In this phase 2, randomized, open-label, crossover trial, patients aged ≥18 years, with EGFR/ALK wild-type tumors and either PD-L1+ (≥ 1%) resected non-small cell lung cancer (NSCLC) (stage 2, 3a, or selected 3b; AJCC 8th edition) with prior chemotherapy and no evidence of recurrence, or untreated PD-L1-high (≥ 50%) stage 4 NSCLC were eligible. Patients, randomized 1:1, received atezolizumab IV or SC for three cycles before switching to the alternative formulation for another three cycles. Patients chose a formulation for the continuation period after cycle 6. Primary endpoint: patient preference for atezolizumab SC/IV.

Results

Among 179 patients randomized, demographics and characteristics were generally balanced between arms. Overall, 87/123 patients (70.7%) preferred atezolizumab SC, of whom 86.2% had a very/fairly strong preference compared with 69.2% of patients who preferred IV (n = 26/123, 21.1%). Patient preference for atezolizumab SC was independent of baseline characteristics and mean injection duration. A higher proportion of preference was seen in patients aged > 74 years (87.5%). A trend for a greater number of patients preferring atezolizumab SC over IV was seen in patients at centers where a higher number of cumulative injections (> 47 to ≤ 164) were administered before preference disclosure.

Conclusions

Most patients preferred atezolizumab SC regardless of baseline characteristics, mean injection duration, and cumulative number of SC injections. The trend for a stronger preference was higher among patients who preferred SC than those who preferred IV. Our findings suggest that the proportion of preference for atezolizumab SC over IV is highest in patients aged > 74 years, and that administrator’s experience could be an important factor influencing patient preference.

Clinical Trial Registration Number

NCT05171777.